Reimbursed Care Access in Hong Kong

Currently classified as a strictly controlled substance under Hong Kong's Dangerous Drugs framework, with no authorised medical use outside of approved clinical research. Possession, supply or trafficking are prosecutable under the Dangerous Drugs Ordinance; public authorities have explicitly warned that "magic mushrooms" (psilocybin/psilocin) fall within Schedule I-type controls. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorised medical use outside of approved clinical research. Hong Kong law treats MDMA ("ecstasy") as a dangerous drug and provides criminal penalties for possession, trafficking and manufacture; sentencing guidance and public material emphasise heavy penalties for trafficking and supply. # #.

Esketamine (intranasal; Spravato®) has been appraised and listed on the Hospital Authority (HA) Drug Formulary in Hong Kong, and the HA Drug Advisory Committee (DAC) outcome records an approval decision for esketamine. This makes regulated hospital-sector use possible within the HA framework; however its deployment is managed as a specialist / special-access therapy rather than a routinely reimbursed outpatient pharmaceutical, and clinical administration is performed under supervised, protocolised conditions. # #.

Practical availability: private psychiatric and specialist clinics in the Greater China region (including Hong Kong-based private providers) advertise esketamine treatment pathways and risk‑management models for treatment‑resistant depression, indicating that private-sector access (self‑pay or insurance-dependent) exists in addition to controlled public-hospital channels; however public reimbursement and broad community coverage is limited and subject to HA operational decisions and criteria. Examples of private providers noting local availability and supervised administration requirements are published clinic pages. #.

Regulatory / clinical context: HA listing indicates regulatory acceptance for specific indications (e.g., treatment‑resistant depression) under controlled conditions; clinicians and services must follow local HA/specialist protocols and risk-management (supervised dosing, monitoring) when delivering esketamine therapy. For patients this generally means specialist referral and treatment delivered in-hospital or in designated clinic settings, with funding arrangements varying by whether the treatment is provided within HA public services or privately (self‑financed). #.

Ketamine is a listed dangerous drug in Hong Kong (and was moved to the more stringent control regime in 2000) but remains an authorised medicinal product for legitimate clinical uses — primarily as an anaesthetic in hospitals — and can be legally supplied on prescription through registered pharmacies and medical facilities under the Pharmacy and Poisons / Poisons List regulatory framework. The government information notice on ketamine's control explicitly notes its licensed medical uses (general anaesthetic) while warning about abuse and criminal penalties for unauthorised supply or possession. # #.

Off‑label psychiatric use: Intravenous and intranasal ketamine protocols for depression are provided in private practice in Hong Kong and regionally; such use is typically off‑label, delivered in private clinics or specialist hospital settings, and is normally not covered as a standard reimbursed outpatient therapy by public funding. Private clinics and specialist services commonly offer ketamine infusion or intranasal ketamine for treatment‑resistant depression as self‑funded care; public sector routine reimbursement is not the norm. Clinicians delivering off‑label ketamine psychiatry must observe drug control, prescribing and institutional governance requirements and ensure treatments occur in supervised medical settings. (See HA Drug Formulary listing for ketamine as an anaesthetic product used within the public system.) # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (dimethyltryptamine) is treated as a dangerous drug in Hong Kong and is subject to criminal penalties for unauthorised possession, supply or trafficking. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT and related tryptamines are treated as dangerous drugs under Hong Kong law; possession, supply and trafficking are prosecutable offences except under explicitly approved research or medical channels. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no authorised therapeutic programme for ibogaine in Hong Kong; possession or supply would be prosecuted under the Dangerous Drugs Ordinance unless part of a formally approved research protocol. # #.

Ayahuasca preparations (DMT‑containing brews) fall under the same controlled-drug framework as DMT and are therefore classified as dangerous; there is no authorised medical use for ayahuasca outside approved clinical research, and importation/possession can lead to prosecution under the Dangerous Drugs Ordinance. Authorities have explicitly cautioned against carrying plant- or product-based controlled substances into Hong Kong. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and peyote‑related substances are treated as dangerous drugs in Hong Kong; possession, cultivation, supply or trafficking are prosecutable except where specifically authorised for research. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Phenethylamine derivatives (2C family and similar substituted phenethylamines) are included in Hong Kong's dangerous drugs regulatory ambit and are prosecutable for possession, supply or distribution. Use is therefore limited to formally authorised research under regulatory oversight. # #.